Back to Journals » Therapeutics and Clinical Risk Management » Volume 13

Cost-effectiveness analysis of dolutegravir plus backbone compared with raltegravir plus backbone, darunavir+ritonavir plus backbone and efavirenz/tenofovir/emtricitabine in treatment naïve and experienced HIV-positive patients

Total article views   HTML views PDF downloads Totals
12,946 Dovepress* 11,625+ 1,798 13,423
PubMed Central* 1,321 460 1,781
Totals 12,946 2,258 15,204
*Since 29 June 2017
Total mentioned Facebook Delicious Reddit Twitter Others
4 0 0 0 0 4

View citations on PubMed and Google Scholar